 Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18 over the last 5 trading days, after the company disclosed in regulatory filings that CEO Laurent Fischer and Chairman Patrick Machado together bought close to. 